Immunotherapy News and Research

Latest Immunotherapy News and Research

Ibrutinib may effectively combat chronic lymphocytic leukemia

The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL), according to studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

10 Dec 2012

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Celldex Therapeutics, Inc. today announced final results from the Company's randomized Phase 2b EMERGE study of CDX-011 in patients with glycoprotein NMB (GPNMB)-expressing, advanced, heavily pretreated breast cancer.

9 Dec 2012

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Scancell Holdings Plc, the developer of therapeutic cancer vaccines, is pleased to announce preliminary results from Part 1 of the Phase 1/2 clinical trial of its DNA ImmunoBody vaccine in patients with Stage III/IV malignant melanoma.

6 Dec 2012

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.

4 Dec 2012

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference.

4 Dec 2012

Certain patients with prostate cancer may benefit from Provenge clinical trial

Select patients with advanced prostate cancer may benefit from a Georgia Health Sciences University Cancer Center clinical trial that looks to improve survival rates of the FDA-approved prostate cancer drug Provenge.

4 Dec 2012

New study finds chemicals used for water purification can lead to food allergies

Food allergies are on the rise, affecting 15 million Americans. And according to a new study published in the December issue of Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI), pesticides and tap water could be partially to blame.

3 Dec 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

CEL-SCI's Multikine cancer drug receives key Japanese patent

CEL-SCI Corporation today announced that the Japanese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine (Leukocyte Interleukin, Injection).

29 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

Alzheimer's therapeutic trials have gotten bad press lately, but it is not all gloom and doom. As evident at the 5th Clinical Trials in Alzheimer's Disease (CTAD) conference, held 29-31 October in the Principality of Monaco, scientists keep extracting new data from recent drug trials to gear up for a round of new ones that aim to tackle Alzheimer's earlier than ever before.

21 Nov 2012

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

In a breakthrough for nanotechnology and multiple sclerosis, a biodegradable nanoparticle turns out to be the perfect vehicle to stealthily deliver an antigen that tricks the immune system into stopping its attack on myelin and halt a model of relapsing remitting multiple sclerosis (MS) in mice, according to new Northwestern Medicine research.

19 Nov 2012

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

UBM Medica US announces that Cancer Network and the journal ONCOLOGY are presenting a two part primer report on targeted therapies in solid tumors.

17 Nov 2012

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, announces positive preliminary results from a Phase II trial investigating the use of ImmunoPulse in metastatic melanoma patients at the 6th World Meeting of Interdisciplinary Melanoma Skin Cancer Centres & 8th EADO Congress.

15 Nov 2012

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Myasthenia gravis (MG) is an autoimmune disease that produces weakness and fatiguability of muscles. It affects between 1 and 7 people per 10,000, according to the best statistics.

15 Nov 2012

Lung cancer stem cells can be isolated and grown in preclinical models

A University of Cincinnati (UC) Cancer Institute lung cancer research team reports that lung cancer stem cells can be isolated-and then grown-in a preclinical model, offering a new avenue for investigating immunotherapy treatment options that specifically target stem cells.

14 Nov 2012

Internet may foresee height of allergy suffering

While it's believed that Nostradamus' prophecies predicted many historical events, his digital successor, the Internet, may be foreseeing the height of allergy suffering. According to allergist Leonard Bielory, M.D., American College of Allergy, Asthma and Immunology (ACAAI) board member, Google search volume is shedding light on the most common allergy symptoms, when searches peak and how they pertain to pollen types.

9 Nov 2012

Lone star tick causes alpha-gal meat sensitivity in regional population

Meat lovers living in the central and southern regions of the country might be opting for a vegetarian lifestyle if meat comes with an unwanted side of a life-threatening allergic reaction. According to a study presented at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI), the lone star tick inhabiting these regions is the primary reason for what's known as a meat induced alpha-gal allergic reaction.

9 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

More than half of allergic children can tolerate baked hen's eggs

Avoiding sweet treats like pumpkin bread and cookies this holiday season might not be necessary for children with egg allergies. New studies presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting found 56 percent of allergic children can tolerate baked hen's egg, while 55 percent outgrow their egg allergy entirely.

9 Nov 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Ibrutinib may effectively combat chronic lymphocytic leukemia

Celldex announces final results from CDX-011 Phase 2b study on GPNMB-expressing breast cancer

Scancell announces preliminary results from Part 1 of ImmunoBody vaccine Phase 1/2 MM trial

Rethinking therapy decisions in autoimmune encephalopathy

Data from OncoSec Medical clinical studies to be presented at DNA Vaccines 2012 Conference

Certain patients with prostate cancer may benefit from Provenge clinical trial

New study finds chemicals used for water purification can lead to food allergies

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

CEL-SCI's Multikine cancer drug receives key Japanese patent

mRNA vaccines offer protection against influenza A virus infections in various animal models

Scientists extract recent drug trials to tackle Alzheimer's earlier than ever before

New nanoparticle halts relapsing remitting multiple sclerosis in mouse model

Cancer Network, ONCOLOGY present two part primer report on targeted therapies in solid tumors

Positive preliminary results from ImmunoPulse Phase II trial in metastatic melanoma

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Lung cancer stem cells can be isolated and grown in preclinical models

Internet may foresee height of allergy suffering

Lone star tick causes alpha-gal meat sensitivity in regional population

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

More than half of allergic children can tolerate baked hen's eggs

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Immunotherapy News and Research

Latest Immunotherapy News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in